Welcome to LookChem.com Sign In|Join Free

CAS

  • or

14003-34-0

Post Buying Request

14003-34-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

14003-34-0 Usage

Chemical Properties

brown powder

Check Digit Verification of cas no

The CAS Registry Mumber 14003-34-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,4,0,0 and 3 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 14003-34:
(7*1)+(6*4)+(5*0)+(4*0)+(3*3)+(2*3)+(1*4)=50
50 % 10 = 0
So 14003-34-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H8N2O/c1-6-9(12)11-8-5-3-2-4-7(8)10-6/h2-5H,1H3,(H,11,12)

14003-34-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (H51733)  3-Methyl-2(1H)-quinoxalinone, 97%   

  • 14003-34-0

  • 1g

  • 578.0CNY

  • Detail
  • Alfa Aesar

  • (H51733)  3-Methyl-2(1H)-quinoxalinone, 97%   

  • 14003-34-0

  • 5g

  • 2102.0CNY

  • Detail

14003-34-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-methyl-1H-quinoxalin-2-one

1.2 Other means of identification

Product number -
Other names 2(1H)-Quinoxalinone,3-methyl

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:14003-34-0 SDS

14003-34-0Relevant articles and documents

Solid-Phase Synthesis of 3,4-Dihydroquinoxalin-2(1H)-ones via the Cyclative Cleavage of N-Arylated Carboxamides

Carbain, Benoit,Schütznerová, Eva,P?ibylka, Adam,Krchňák, Viktor

, p. 701 - 706 (2016)

We describe a practical (time-efficient, with commercially available building blocks, user friendly reaction conditions, high purity of products) synthesis of pharmacologically relevant quinoxalinones with three points of diversification that takes advantage of solid-phase synthesis and cyclative cleavage. Resin-bound (S)-2-(N-alkyl-2-nitrophenyl)sulfonamide-3-alkyl-N-(2-hydroxyethyl)propanamides, which are accessible from Fmoc-protected α-amino acids, 2-nitrobenzenesulfonyl chloride and alcohols, underwent base-mediated N-arylation. The reduction of the nitro group produced acyclic intermediates that were subjected to acid-mediated cyclative cleavage to yield 3,4-dihydroquinoxalin-2(1H)-ones.

Synthesis of novel quinoxalines by ring transformation of 3-quinoxalinyl-1,5-benzodiazepine

Kurasawa,Shimabukuro,Okamoto,Takada

, p. 1461 - 1464 (1985)

-

Facile synthesis of novel 3-quinoxalinyl-1,5-benzodiazepines via ring transformation. Stable tautomers in the 1,5-benzodiazepin-2-one ring system [1]

Kurasawa,Okamoto,Ogura,Takada

, p. 661 - 664 (1985)

-

Reaction-Based Color-Convertible Fluorescent Probe for Ferroptosis Identification

Shi, Leilei,Guan, Qinghua,Gao, Xihui,Jin, Xin,Xu, Li,Shen, Jian,Wu, Chenwei,Zhu, Xinyuan,Zhang, Chuan

, p. 9218 - 9225 (2018)

Ferroptosis is an iron-mediated, caspase-independent pathway of cell death that is accompanied with the accumulations of reactive oxygen species (ROS) and oxygenases, as well as being involved in many other pathophysiological procedures. However, specific and rapid monitoring of ferroptosis in living cells or tissues has not been achieved so far. Herein, a quinoxalinone-based fluorescent probe (termed as Quinos-4, or QS-4) with a reactive aromatic thioether moiety was designed for ferroptosis identification. Upon exposing it to high levels of ROS and hemeoxygenase-1 (HO-1), which are considered as the biochemical characteristics of ferroptosis, QS-4 could be oxidized into a sulfoxide derivative (QSO-4) and its original aggregation-induced enhanced red fluorescence emission could be converted to green fluorescence emission sharply. On the basis of this unique reaction-induced color conversion, this molecular probe can be employed for identifying the occurrence of ferroptosis both in vitro and in vivo.

-

Korshak et al.

, (1971)

-

-

Titov,Kozhokina

, p. 1105 (1973)

-

Synthesis, crystal structure and calculation of oxides of 2-methylamino-3-methyl quinoxaline

Li, Junjian,Wang, Rui,Wang, Wenfeng,Wang, Xucheng,Yuan, Yaofeng,Zhang, Min

, (2020)

Monoxide and dioxide of animo quinoxaline were synthesized and characterized by 1H NMR, 13C NMR and HRMS. The result shows that monoxide is main product. 1H NMR analysis, quantum calculation and crystal structure all indicate that the monoxide is 4-oxide structure but not 1-oxide structure. The subsequent discussions of electronic effect and steric effect of 1-oxide and 4-oxide support the conclusion that 4-oxide is dominant product, which is consistent with 1H NMR analysis and crystal structure. At last, the calculated structure is in good agreement with the crystal structure in this paper, which indicates that the calculation result in this paper is credible.

-

Hoffman,Killinger

, p. 162 (1969)

-

Qualitative Profiling of Polyglucose Degradation Products in Peritoneal Dialysis Fluids

Gensberger, Sabrina,Knabner, Carina,Waibel, Reiner,Huppert, Jochen,Pischetsrieder, Monika

, p. 6103 - 6111 (2015)

Heat sterilization of peritoneal dialysis (PD) fluids leads to partial degradation of the osmotic agent to form reactive carbonyl structures, which significantly reduce the biocompatibility of PD fluids and impair long-term PD therapy. Hence, it is important to know the exact composition of the degradation products to improve biocompatibility of PD fluids. Our study conducted targeted screening for degradation products in polyglucose (icodextrin)-containing PD fluids (pGDPs) by applying o-phenylenediamine (OPD) to form stable derivatives, which were analyzed by ultrahigh-performance liquid chromatography with hyphenated diode array tandem mass spectrometry (UHPLC-DAD-MS/MS). For the first time, specific degradation products of polyglucose, namely, 4-deoxyglucosone (4-DG) and 3,4-dideoxypentosone (3,4-DDPS), could be identified in PD fluids. Further, a reaction product of 5-hydroxymethylfurfural (5-HMF) and OPD could be characterized to be (5-(1H-benzo[d]imidazol-2-yl)furan-2-yl)methanol. Additionally, 3-deoxyglucosone (3-DG) and 3-deoxygalactosone (3-DGal), both known to be present in glucose-based PD fluids, were also detected in polyglucose-containing fluids. Trapping a hitherto unknown degradation product with OPD yielded 1,4-bis(1H-benzo[d]imidazol-2-yl)-3,4-dihydroxybutan-1-one, which was present in heat- as well as filter-sterilized PD fluids.

Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists

Ibrahim, Mohammed K.,Eissa, Ibrahim H.,Abdallah, Abdallah E.,Metwaly, Ahmed M.,Radwan,ElSohly

, p. 1496 - 1513 (2017)

In our effort to develop potent anti-hyperglycemic agents with potential agonistic activities toward PPARγ and SUR, three novel series of quinoxaline derivatives bearing sulfonylurea or sulfonylthiourea moieties with different linkers were designed and synthesized. Some of the newly synthesized compounds were evaluated in vivo for their anti-hyperglycemic activities in STZ-induced hyperglycemic rats. Compounds 15a, 15e, 19band 24aexhibited the highest anti-hyperglycemic activities with % reduction in blood glucose level of (50.58, 43.84, 45.10 and 49.62, respectively). Additionally, eight compounds revealed potent anti-hyperglycemic activities were further evaluated in vitro for their PPARγ binding affinity and insulin-secreting ability as potential mechanisms for anti-hyperglycemic activity. Four compounds (15a, 15b, 15dand 15e) significantly bound to PPARγ with IC50values of 0.482, 0.491, 0.350 and 0.369 μM, respectively. Moreover, Compounds 15aand 15bhave demonstrated induction of insulin-secretion with EC50values of 0.92 and 0.98 μM, respectively. Furthermore, molecular docking and pharmacophore generation techniques were carried out to investigate binding patterns and fit values of the designed compounds with PPARγ and SUR, respectively.

Novel antioxidant quinoxaline derivative: Synthesis, crystal structure, theoretical studies, antidiabetic activity and molecular docking study

Missioui, Mohcine,Mortada, Salma,Guerrab, Walid,Serdaro?lu, Goncagül,Kaya, Sava?,Mague, Joel T.,Essassi, El Mokhtar,Faouzi, My El Abbes,Ramli, Youssef

, (2021)

New quinoxaline derivative, N-(4-methyl-2-nitrophenyl)-2-(3-methyl-2-oxoquinoxalin-1(2H)-yl)acetamide (NPOQA) has been synthesized and characterized by IR, 1H &13C NMR, ESI-MS and single crystal X-ray diffraction analysis using exper

Small molecule compound bonded with alpha-synuclein aggregate, and preparation method and application thereof

-

Paragraph 0024, (2021/04/14)

The invention belongs to the technical field of medicine, and relates to a compound capable of being bonded with alpha-synuclein aggregate, and a preparation method and application thereof. The structural general formula of the compound is shown in the formula I, wherein m is a positive integer selected from 1 to 3, R1 is respectively selected from phenyl, substituted phenyl, naphthyl, biphenyl, 5-6-membered aromatic heterocycle and substituted 5-6-membered aromatic heterocycle, and R2 is selected from benzyl, C1-3 alkyl naphthyl, C1-3 alkyl, phenyl, substituted phenyl, 5-6-membered heteroaromatic ring and substituted 5-6-membered heteroaromatic ring. The compound disclosed by the invention can be strongly bonded with alpha-synuclein aggregate, can be used as an imaging tracer agent required by image examination technologies such as PET (Polyethylene Terephthalate) and SPECT (Single Photon Emission Computed Tomography) for clinical disease diagnosis or used for preparing the imaging tracer agent and preparing a composition comprising the imaging tracer agent, and used for detecting diseases related to alpha-synuclein misfolding and abnormal aggregation, such as Parkinson's disease, and has a remarkable good application prospect.

Aggregation-induced emission photosensitizer, preparation method and application

-

Paragraph 0033-0034, (2021/06/23)

The invention provides an aggregation-induced emission photosensitizer based on a quinoxaline ketone skeleton, and a preparation method and application thereof. A photosensitizer molecule is prepared from o-phenylenediamine and a derivative thereof through cyclization, nucleophilic substitution, aldol condensation and Suzuki coupling reaction. The compound provided by the invention has strong near-infrared fluorescence emission in an aggregation state, generates a large amount of reactive oxygen free radicals under the radiation of a 530 nm laser, and can be used as a potential photosensitizer. The compound provided by the invention can be directly added into a culture medium for photodynamic therapy of tumor cells, and can also be prepared into nano particles for intravenous injection to perform in-vivo photodynamic therapy.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 14003-34-0